ADVERTISEMENT
Ajanta Pharma Q2 Review — Strong Growth Momentum In The US; Systematix Maintains 'Buy'
The brokerage retains its forecasts on Ajanta and maintains Buy with a target price of Rs 3,293 based on 35x FY27E earnings per share.
04 Nov 2025, 12:12 PM IST 
Save
Ajanta Pharma's growth is primarily attributed to five new launches made in H2 FY25 and few new launches in this quarter.
(Source: pexels/Pietro Jeng)
Ajanta Pharma continues to add to its filed force in emerging markets and India which should help it sustain the double-digit growth. New therapies in gynecology and nephrology are gaining traction and are expected to contribute meaningfully to India business.
